RMTINasdaqPharmaceutical PreparationsFiscal year ends December 31
ROCKWELL MEDICAL, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.49+0.06 (+0.81%)
Close on Oct 19, 2026
- Market cap
- $29.65M
- P/E (TTM)
- –
- Dividend yield
- –
ROCKWELL MEDICAL, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concentrate Product | – | $101.44M | $81.27M | $71.65M | $60.86M | $61.06M | $60.76M | $63.12M | $57.07M | – | – | – |
| License | – | – | – | $2.70M | $2.20M | $2.20M | $2.30M | $2.40M | – | – | – | – |
| Product | – | – | – | $70.10M | $59.70M | $60.00M | $59.00M | $61.00M | – | – | – | – |
| Drug Revenues | – | $46.00K | $2.34M | $1.16M | $1.08M | $1.14M | $545.00K | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $60.36M | $92.26M | $74.34M | $65.77M | $55.39M | $56.58M | $54.79M | $54.39M | $50.41M | – | 87.1% | -34.6% |
| Rest of World | $8.90M | $9.23M | $9.27M | $7.05M | $6.54M | $5.62M | $6.51M | $9.00M | $6.89M | – | 12.9% | -3.6% |
From the segment and revenue-disaggregation notes of Rockwell Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.